In the News
Is fraud the business model of the prescription drug industry?
20th December 2016
Yes according to Democrat Bernie Sanders who is using the inter-regum between the Presidential election and the inauguration of Donald Trump to push his campaign alleging price gouging by the leading US pharmaceutical giants.
More here
I was struck in particular by an article in the FT that claimed the price of a routine anti-worming treatment is hundreds of times more expensive in the US than it is when paying over-the-counter in the UK. The brand Impax sells tapeworm treatment course for $880 v £3.50 in UK for the same treatment Ovex.
More here from the Guardian
Could Pfizer's record fine for unfair prices change the industry's practices? https://t.co/EuULJzzLFj
— Guardian Business (@BusinessDesk) December 9, 2016
- Economics
- Blog
- In the News
- Monopoly
- Supernormal profit
- Anti-Competitive Behaviour
- Price Gouging
- Market Power
Geoff Riley
Geoff Riley FRSA has been teaching Economics for over thirty years. He has over twenty years experience as Head of Economics at leading schools. He writes extensively and is a contributor and presenter on CPD conferences in the UK and overseas.
You might also like
What is Market Concentration?
Study Notes
Profit Concepts Defined
Study Notes
Topical Examples of Price Discrimination
Study Notes
Price Discrimination and Economic Welfare
Topic Videos
Advantages and Disadvantages of Price Discrimination
Topic Videos
Price Discrimination and Consumer Welfare - A-Level Economics Essay Walkthrough
Practice Exam Questions
3.4.5 Monopoly Entry Barriers (Edexcel A-Level Economics Teaching PowerPoint)
Teaching PowerPoints
Un-bottling the Baby Formula Market: Why Competition Matters for Families
12th November 2024